MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q3
hinzugefügt 16.11.2023
Athersys Operativer Cashflow 2011-2026 | ATHX
Operativer Cashflow Jährlich Athersys
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -76.2 M | -61.8 M | -35.3 M | -13.4 M | -24 M | -10.9 M | - | - | -22.8 M | -17.7 M | -14.5 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -10.9 M | -76.2 M | -30.7 M |
Operativer Cashflow Vierteljährlich Athersys
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -5.97 M | - | -47 M | -36.6 M | -20.2 M | - | -56.9 M | -37.2 M | -17.1 M | - | -44.5 M | -24.8 M | -12.1 M | - | -25.2 M | -17 M | -5.52 M | - | -8.78 M | -1.29 M | -5.68 M | - | -17.9 M | -11.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.11 M | - | -14 M | -10.4 M | -5.42 M | - | -10 M | -5.85 M | -1.8 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -1.29 M | -56.9 M | -17.9 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
-29.7 M | $ 2.62 | 28.82 % | $ 147 M |  China |
 |
GlaxoSmithKline plc
GSK
|
7.95 B | $ 48.98 | 0.68 % | $ 173 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.51 | 7.34 % | $ 8.45 B |  Australia |
 |
Grifols, S.A.
GRFS
|
597 M | $ 9.25 | 1.49 % | $ 6.83 B |  Spain |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Galapagos NV
GLPG
|
-504 M | $ 34.61 | 0.61 % | $ 2.69 B |  Belgium |
 |
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 3.1 | 4.49 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Zoetis
ZTS
|
2.95 B | $ 123.99 | -0.31 % | $ 56.3 B | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 116.27 | -1.86 % | $ 27.2 B | Germany |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 235.41 | 2.95 % | $ 5 B |  Danmark |
 |
Burford Capital Limited
BUR
|
181 M | $ 9.74 | -1.37 % | $ 1.55 B | Britain |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
180 M | $ 67.49 | -3.02 % | $ 9.03 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 4.51 | 8.41 % | $ 9.81 B | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
213 M | $ 25.92 | -0.86 % | $ 1.26 B | USA |
 |
Amneal Pharmaceuticals
AMRX
|
295 M | $ 13.49 | -0.66 % | $ 4.17 B | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.66 | -1.85 % | $ 16.7 M | USA |
 |
AstraZeneca PLC
AZN
|
5.96 B | $ 92.87 | 1.28 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
2.88 B | $ 171.89 | -1.1 % | $ 25 B | USA |